



Published in final edited form as:

Leukemia. 2018 February ; 32(2): 547–549. doi:10.1038/leu.2017.293.

A new mouse expressing human Fc γ receptors to better predict therapeutic efficacy of human anti-cancer antibodies

Emily Casey^{1,2}, Stylianos Bournazos³, George Mo², Patrizia Mondello², Kay See Tan⁴, Jeffrey V. Ravetch³, and David A. Scheinberg^{1,2,5,*}

¹Gerstner Sloan Kettering Graduate School, Memorial Sloan Kettering, New York, NY 10065

²Molecular Pharmacology Program, Memorial Sloan Kettering, New York, NY 10065

³Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065

⁴Epidemiology & Biostatistics, Memorial Sloan Kettering, New York, NY 10065

⁵Weill Cornell Medicine, New York, NY, 10065

Keywords

cancer immunology; antibody therapy; Fc γ receptors; xenografting; thrombocytopenia; rituximab; obinutuzumab

The mechanisms of action of cytotoxic monoclonal antibodies (mAbs) include direct effects via agonistic or antagonistic binding, and Fc γ R-dependent mechanisms to induce antibody-dependent cell cytotoxicity (ADCC). Fc γ R engagement has been shown to be the critical determinant of mAb therapeutic efficacy in humans^{1,2}. An antibody's Fc domain's relative affinity for the activating and inhibitory Fc γ R, called the A/I ratio, can determine its functional output³, and is directly correlated to therapeutic efficacy *in vivo*⁴. This has spawned recent efforts to engineer antibodies with enhanced activating Fc γ R affinity.

Only 14% of promising mAb therapies prove effective in patients and most do not make it to the market, despite strong preclinical efficacy *in vivo*⁵. Anti-cancer antibodies are even less successful than those for other indications. This problem calls for better predictive models that can more efficiently determine whether an antibody will succeed in the clinic.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*To whom correspondence should be addressed: Scheinbd@mskcc.org.

Author contributions: E.C. conceived and performed mouse breeding and colony maintenance, flow cytometry characterization of new mice strains, ITP model experiments, lymphoma antibody therapy experiments, and authored the manuscript. S.B. contributed to the conception of breeding scheme and experimental plans, contributed mice and antibody resources, performed the antibody-Fc γ R SPR analysis, and contributed methods and edited the manuscript. G.M. and P.M. contributed to mouse characterization experiments and edited the manuscript. K.S.T. performed statistical analysis, contributed to the methods, and edited the manuscript. J.V.R. contributed mice and other resources and edited the manuscript. D.A.S. contributed resources and helped guide the planning and execution of the experiments and edited the manuscript.

Competing interests: A patent has been filed by MSKCC encompassing these novel mouse strains.

The critical differences between mouse and human Fc γ R networks may cause the poor predictive power of preclinical models (Figure 1A). Neutrophils from humans, but not from mice, express hFc γ RIIB. Mouse NK cells express mFc γ RIII, while human NK cells express hFc γ RIIIA. mFc γ RIII has been shown to modestly contribute to mAb efficacy *in vivo*⁶, with mFc γ RIV being the critical receptor for antibody therapy. Meanwhile, hFc γ RIIIA is a key mediator of antibody therapy in humans². Furthermore, differences in the level of cellular expression results in different thresholds for activation. Human IgG1—the human antibody subclass with the highest capacity for ADCC—has large affinity differences for mouse and human Fc γ Rs, which may change functional output of a hIgG1 tested in a mouse versus a human. Furthermore, with the recent clinical introduction of Fc engineered antibodies, testing of an affinity-enhanced antibody in a mouse lacking its key Fc γ R has little value.

Recently, immune competent mice expressing only the human Fc γ Rs have been created⁷. This mouse contains each of the individual hFc γ R transgenes (hFc γ RI, hFc γ RIIA^{R131}, hFc γ RIIB^{I232}, hFc γ RIIIA^{F158}, and hFc γ RIIIB) under the control of their endogenous promoters and regulatory elements and has proven to be a critical tool for the evaluation and study of hIgGs in models of infectious disease and syngeneic tumor therapy⁸. However, this model has no ability to engraft human cancers that bear human-specific epitopes that are not shared by mice, nor does transgenic expression of such human epitopes in mouse cancers truly reflect the native expression levels. Therefore, a new mouse model expressing human Fc γ Rs in an immune deficient setting is necessary for better preclinical efficacy testing of therapeutic antibodies.

The first step to establish the new immune deficient “RHuFR” mice was to cross immunodeficient Rag2^{-/-} mice that lack mature B and T cells to mouse Fc γ R knockout mice (mFc γ RI^{-/-}, mFc γ R α ^{-/-})⁷, creating Rag2^{-/-} Fc γ R Null mice (Figure 1B). This Fc γ R Null strain successfully demonstrates the loss of mouse Fc γ R expression on all leukocyte populations (Figure S1). This strain was then crossed to the immunocompetent human Fc γ R⁺ mice⁷. The product of this breeding was a Rag2^{-/-} human Fc γ R⁺ mouse (RHuFR). Expression of each hFc γ R on the mouse leukocyte populations in the novel RHuFR mouse recapitulated the human expression pattern (Figure S2, Table S1). Furthermore, mice lacking each of the individual hFc γ Rs were isolated while breeding to create single human Fc γ R “knockout” strains in the Rag2^{-/-} background (Table S2). Loss of the B and T cell populations in the Fc γ R Null, RHuFR, and RHuFR “knockout” strains was also confirmed (Figure S3).

The newly generated RHuFR mice were first used in a model of idiopathic thrombocytopenia purpura (ITP), as a surrogate for *in vivo* antibody-dependent cytotoxicity by employing an anti-platelet hIgG1. The RHuFR mice achieved platelet depletion, comparable to what is reported for the immunocompetent human Fc γ R⁺ mice⁷ (Figure S4A). This suggests that the introduction of Rag2 deficiency does not interfere with Fc γ R mediated function in these animals and that Fc γ R function has been maintained from the parental immunocompetent human Fc γ R⁺ mice. The RHuFR “knockout” strains were also used in the ITP model and overall, demonstrated little fluctuation in hFc γ R mediated platelet depletion compared to the parental RHuFR strain (Figure S4B).

Next, to investigate the ability of RHuFR mice to more accurately mimic clinical observations for therapeutic cancer antibodies, we chose two commercially available anti-CD20 antibodies, rituximab and obinutuzumab, which substantially differ in human clinical activity. Rituximab contains a wild type hIgG1 heavy chain constant region, while obinutuzumab contains a hIgG1 heavy chain constant region with decreased levels of fucosylated oligosaccharides resulting in enhanced binding to hFcγRIIIA and thus enhanced ADCC activity. A recent Phase III study in patients with CLL demonstrated that the Fc enhanced obinutuzumab confers a significantly higher response rate and survival advantage over rituximab therapy⁹.

We first investigated antibody pharmacokinetics. For both antibodies, Rag2^{-/-} mouse FcγR + mice had prolonged antibody blood half-lives, while the RHuFR mice had extremely short antibody kinetics (Figure S5). Human FcγRI is the only high affinity human FcγR that binds soluble, monomeric IgG. The high degree of homology between human and mouse FcγRI, as well as their IgG binding affinity suggest that human FcγRI has likely limited contribution to the cytotoxic activity of anti-tumor mAbs *in vivo*^{6, 10}. Indeed, for several therapeutic antibodies, clinical response to therapy has been shown to be associated with SNPs of the low affinity FcγRs, FcRγIIIa and FcγRIIa, but not with FcγRI. Furthermore, mechanistic studies on the role of human FcγRs in the *in vivo* activity of anti-CD20 antibodies revealed that cytotoxicity against tumor targets is mediated exclusively through FcγRIIIa-mechanisms.

Therefore, we employed the RHuFR derivative strain that lacks human FcγRI (RHuFR¹⁻) to remedy this kinetic discrepancy (Figure S5), thereby allowing for an antibody-dosing regimen to compare therapeutic effects between the RHuFR¹⁻ and the Rag2^{-/-} mouse FcγR + mice. Importantly, the RHuFR¹⁻ mouse expresses all other human FcγRs in the same manner as in the RHuFR mice (Figure S6) and is functionally intact, showing identical platelet clearance to the RHuFR mouse in the ITP model (Figure S4B). Furthermore, since the main focus of this study is the generation of mouse strains for the study of Fc effector function *in vivo*, the humanization of FcRn was not necessary given that FcRn function is to regulate IgG half-life and not effector function.

Rag2^{-/-} mice expressing either the mouse FcγRs or human FcγRs (RHuFR¹⁻) were engrafted with the CD20+ Daudi human lymphoma cell line and treated with rituximab or obinutuzumab. The affinities of rituximab and obinutuzumab for the relevant mouse and human FcγRs were measured (Figure 2A, Figure S7). As FcγRI is not present in the mouse strains used, affinity values have been omitted for clarity. The Fc engineering of obinutuzumab results in a significant increase in affinity for hFcγRIIIA, with little to no increase in affinity for activating mouse FcγRs. In the mouse FcγR+ mice, no significant therapeutic response benefit for rituximab was observed, while obinutuzumab resulted in a less than 1 log decrease in overall tumor signal as compared to untreated (p=0.0072) (Figure 2B & 2C). However, obinutuzumab therapy did not confer a survival advantage over rituximab therapy in the mouse FcγR+ mice (Figure 2C).

In contrast, rituximab modestly slowed lymphoma growth in the RHuFR¹⁻ mice, while obinutuzumab achieved significant eradication of the lymphoma with a ~1 vs. ~2 log

reduction in tumor burden from untreated, respectively (Figure 2B–C). Moreover, by Day 28, 9/10 mice on obinutuzumab therapy had no detectable tumor burden, while only 4/10 mice on rituximab therapy showed no detectable tumor (Figure S8). Both rituximab and obinutuzumab treatment resulted in increased median survival compared to untreated and isotype treated mice (Figure 2C). Moreover, a significant survival advantage for obinutuzumab vs. rituximab treated RHuFR¹⁻ mice was seen. These data directly mimic the enhanced human clinical response rates and prolonged progression free survival trends observed for obinutuzumab over rituximab⁹. Furthermore, these data support the importance of testing Fc enhanced therapeutic antibodies in the setting of the human FcγR network.

In contrast to the traditional immunodeficient model with mouse FcγRs, the RHuFR¹⁻ mice reproduced the clinical observations for rituximab vs. obinutuzumab therapy. In addition, the RHuFR derivative strains lacking one or more hFcγRs will allow for the probing of the individual roles of each receptor in both pharmacology and therapy, as demonstrated in the inflammatory ITP model. This is especially important to quickly identify the receptors responsible for mAb therapy *in vivo* and subsequently direct Fc engineering of the antibody. Furthermore, crossing these RHuFR “knockout” strains can quickly create mice containing combinations of human FcγR “knockouts” for probing receptor interactions and redundancy in function. Overall, these mice are tools to expand our understanding of the complexity of the human FcγR network and how individual antibody targets (e.g. epitope, target cell type, microenvironment, etc.) can greatly shape the observed therapeutic effect for a given antibody.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Dr. Michael Kharas provided the Hemavet machine and Dr. Joseph Sun supplied the anti-NK1.1 (PK136) antibody. Dr. Dmitry Pankov, Dr. Katja Behling, and Aaron Chang assisted with mouse work.

Funding: The work was supported by: a Ruth L. Kirschstein National Research Service Award (F31 CA189305 to E.C.), NIH R01 CA55349, P01 CA33049, CCSG P30-008749 to D.A.S., The Tudor Fund, Lymphoma Foundation, and The Center for Experimental Therapeutics to D.A.S.; American Foundation for AIDS Research Mathilde Krim Fellowship in Basic Biomedical Research (109519-60-RKVA) to S.B., and the NIH P01 CA190174 and R35 CA196620 to J.V.R. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Cartron G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood*. 2002; 99:754–758. [PubMed: 11806974]
2. Weng WK, Levy R. Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma. *Journal of Clinical Oncology*. 2003; 21:3940–3947. [PubMed: 12975461]
3. Clark MR. IgG Effector Mechanisms. *Chemical Immunology*. 1996; 65:88–110.
4. Nimmerjahn F, Ravetch JV. Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding. *Science*. 2005; 310:1510–1512. [PubMed: 16322460]
5. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. *Nat Biotech*. 2014; 32:40–51.

6. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. Fc γ RIV: A Novel FcR with Distinct IgG Subclass Specificity. *Immunity*. 2005; 23:41–51. [PubMed: 16039578]
7. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fc γ receptor structural and functional diversity. *Proceedings of the National Academy of Sciences*. 2012; 109:6181–6186.
8. Bournazos, S., DiLillo, DJ., Ravetch, JV. *Fc Receptors*. Daeron, M., Nimmerjahn, F., editors. Springer International Publishing; Cham: 2014. p. 237-248.
9. Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*. 2014; 370:1101–1110. [PubMed: 24401022]
10. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fc γ receptors regulates B lymphocyte depletion during CD20 immunotherapy. *The Journal of Experimental Medicine*. 2006; 203:743–753. [PubMed: 16520392]




Figure 1. Creation of the immunodeficient human FcγR expressing RHuFR mice

(A) Figure: Human and mouse Fcγ receptors. ITAM (immunoreceptor tyrosine-based activation motif); ITIM (immunoreceptor tyrosine-based inhibitory motif). Table: + indicates receptor expression, - indicates lack of receptor expression, (+) indicates inducible expression, +/- indicates expression on some, but not all, cellular subsets. (B) Breeding scheme used.




Figure 2. The human FcγR⁺ RHuFR¹⁻ mouse is superior to the conventional Rag2^{-/-} mouse in replicating rituximab versus obinutuzumab clinical outcomes

(A) Relative affinities of the relevant mouse and human FcγRs. (B) Bioluminescence imaging of Rag2^{-/-} mouse FcγR⁺ and RHuFR¹⁻ female mice at day 28. (C) Left two curves show total radiance signal (photons/second) and Kaplan-Meier survival curves for Rag2^{-/-} mouse FcγR⁺ mice (n=5 mice/group). Obinutuzumab therapy resulted in a small reduction in overall tumor burden when compared to untreated mice (p=0.0072) and no difference in survival was observed between the two anti-CD20 mAb therapy groups. Right two curves show total radiance signal (photons/second) and Kaplan-Meier survival curves for all RHuFR¹⁻ mice (n= 9–10 mice/group). Obinutuzumab therapy demonstrated significant reductions in tumor burden compared to untreated and isotype (p<0.0001 for both). There was also a significant difference in overall tumor burden between rituximab and obinutuzumab treated groups (p=0.003) and a significant survival advantage for obinutuzumab therapy compared to rituximab therapy (p=0.0088).